NCT02933996

Brief Summary

The coronary artery bypass grafting (CABG) is a surgery to relieve angina and reduce mortality of coronary heart disease. However, the patient is more prone to have immunosuppression after the surgery, causing secondary infection, and it is closely correlated to the occurrence and progress of tumor after surgery. More and more studies revealed that needle puncture was able to effectively regulate the function of immune system. However, its perioperative application is unclear. Therefore, this clinical study is aimed to evaluate whether the effect of transcutaneous acupoint electric stimulation (TEAS) on improvement of immunosuppression of patients after receiving CABG.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 10, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 14, 2016

Completed
1.1 years until next milestone

Study Start

First participant enrolled

December 1, 2017

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 29, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2020

Completed
Last Updated

May 27, 2020

Status Verified

May 1, 2020

Enrollment Period

2.2 years

First QC Date

October 10, 2016

Last Update Submit

May 23, 2020

Conditions

Keywords

immunosuppressioncardiac surgeryTEAS(Transcutaneous electrical acupoint stimulation)postoperative

Outcome Measures

Primary Outcomes (1)

  • Proportion of mHLA-DR positive cell

    Human leukocyte antigen of monocyte (mHLA-DR)

    day before surgery, Day 1 after surgery (one day after surgery), Day 3 after surgery (3 days after surgery), and Day 5 after surgery (5 days after surgery).

Secondary Outcomes (3)

  • Content of serum IL-6

    One day before surgery, Day 1, 3 and 5 after surgery

  • Content of serum CRP

    One day before surgery, Day 1, 3 and 5 after surgery

  • Rate of secondary infection

    Within 7 days after surgery

Study Arms (2)

TEAS+GA group

EXPERIMENTAL

The patients of TEAS+GA group will receive TEAS therapy in perioperative period. GA: general anesthesia

Device: TEAS+GA groupDevice: Sham TEAS+GA group

Sham TEAS+GA group

SHAM COMPARATOR

The patients of Sham TEAS+GA will receive none TEAS in perioperative period.

Device: TEAS+GA groupDevice: Sham TEAS+GA group

Interventions

The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.

Sham TEAS+GA groupTEAS+GA group

No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.

Sham TEAS+GA groupTEAS+GA group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18-75 years, male and female;
  • Patients diagnosed as coronary disease, scheduled to receive CABG;
  • BMI: 18.5kg/m2\<BMI≤30kg/m2;
  • Graded as I-III by American Standards Association(ASA);
  • Patients firstly receiving CABG under extracorporeal circulation.

You may not qualify if:

  • Presence of surgical incision or scar at Zusanli acupoint (ST36) /Shenshu (BL23) acupoint;
  • Patients with local skin infection at acupoint;
  • Patients with nerve injury on upper or lower limbs;
  • Patients with history of spinal surgery;
  • Patients who have participated in other clinical trial in recent 4 weeks;
  • Patients using pacemaker;
  • Patients combined with pain before surgery who are using central analgesic drug or drug abuser (e.g., opioid) and dependent user;
  • Patients combined with severe central nervous system disease or severe mental disease;
  • Patients with alcoholic history;
  • Patients who have received emergent coronary bypass operation due to acute myocardial infarction.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, 201203, China

Location

Related Publications (1)

  • Chen WT, Wei JF, Wang L, Zhang DW, Tang W, Wang J, Yong Y, Wang J, Zhou YL, Yuan L, Fu GQ, Wang S, Song JG. Effects of perioperative transcutaneous electrical acupoint stimulation on monocytic HLA-DR expression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass: study protocol for a double-blind randomized controlled trial. Trials. 2019 Dec 30;20(1):789. doi: 10.1186/s13063-019-3889-z.

Study Officials

  • Jianggang Song, M.D.

    Shuguang Hospital Affiliated to Shanghai University of TCM

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
deputy director of anesthesia

Study Record Dates

First Submitted

October 10, 2016

First Posted

October 14, 2016

Study Start

December 1, 2017

Primary Completion

February 29, 2020

Study Completion

March 31, 2020

Last Updated

May 27, 2020

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will share

Study Protocol will be shared with other researchers.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
The data will become available with 6 months of study completion.
Access Criteria
Data access requests will be reviewed by an extemal independent Review Panel. Requestors will be required to sign a Data Access Agreement.

Locations